+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oligodendroglioma - Pipeline Review, H2 2019

  • ID: 4866575
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 167 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AlfaSigma SpA
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Ipsen SA
  • Pfizer Inc
  • MORE
Oligodendroglioma - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma - Pipeline Review, H2 2019, provides an overview of the Oligodendroglioma (Oncology) pipeline landscape.

Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy surgery and radiation therapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Oligodendroglioma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Oligodendroglioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oligodendroglioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 8, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Phase 0 stages comprises 2, 2 and 1 molecules, respectively.

Oligodendroglioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Oligodendroglioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Oligodendroglioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Oligodendroglioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Oligodendroglioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Oligodendroglioma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Oligodendroglioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Oligodendroglioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AlfaSigma SpA
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Ipsen SA
  • Pfizer Inc
  • MORE
Introduction
Oligodendroglioma - Overview
Oligodendroglioma - Therapeutics Development
Oligodendroglioma - Therapeutics Assessment
Oligodendroglioma - Companies Involved in Therapeutics Development
Oligodendroglioma - Drug Profiles
Oligodendroglioma - Dormant Projects
Oligodendroglioma - Discontinued Products
Appendix

List of Tables
Table 1: Number of Products under Development for Oligodendroglioma, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products by Stage and Target, H2 2019
Table 7: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 8: Number of Products by Stage and Mechanism of Action, H2 2019
Table 9: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 10: Number of Products by Stage and Route of Administration, H2 2019
Table 11: Number of Products by Stage and Molecule Type, H2 2019
Table 12: Oligodendroglioma - Pipeline by AlfaSigma SpA, H2 2019
Table 13: Oligodendroglioma - Pipeline by AngioChem Inc, H2 2019
Table 14: Oligodendroglioma - Pipeline by Astellas Pharma Inc, H2 2019
Table 15: Oligodendroglioma - Pipeline by Bayer AG, H2 2019
Table 16: Oligodendroglioma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Table 17: Oligodendroglioma - Pipeline by Bristol-Myers Squibb Co, H2 2019
Table 18: Oligodendroglioma - Pipeline by CDG Therapeutics Inc, H2 2019
Table 19: Oligodendroglioma - Pipeline by Eli Lilly and Co, H2 2019
Table 20: Oligodendroglioma - Pipeline by GtreeBNT Co Ltd, H2 2019
Table 21: Oligodendroglioma - Pipeline by Immatics Biotechnologies GmbH, H2 2019
Table 22: Oligodendroglioma - Pipeline by Ipsen SA, H2 2019
Table 23: Oligodendroglioma - Pipeline by Northwest Biotherapeutics Inc, H2 2019
Table 24: Oligodendroglioma - Pipeline by Novartis AG, H2 2019
Table 25: Oligodendroglioma - Pipeline by Pfizer Inc, H2 2019
Table 26: Oligodendroglioma - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019
Table 27: Oligodendroglioma - Pipeline by TheraBiologics Inc, H2 2019
Table 28: Oligodendroglioma - Pipeline by Tocagen Inc, H2 2019
Table 29: Oligodendroglioma - Dormant Projects, H2 2019
Table 30: Oligodendroglioma - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Oligodendroglioma, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AlfaSigma SpA
  • AngioChem Inc
  • Astellas Pharma Inc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • CDG Therapeutics Inc
  • Eli Lilly and Co
  • GtreeBNT Co Ltd
  • Immatics Biotechnologies GmbH
  • Ipsen SA
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Pfizer Inc
  • Taiho Pharmaceutical Co Ltd
  • TheraBiologics Inc
  • Tocagen Inc
Note: Product cover images may vary from those shown
Adroll
adroll